The number of drug authorizations for the world's top 12 pharmaceuticals companies increased to...
The number of drug authorizations for the world's top 12 pharmaceuticals companies increased to 41 over the past year from 32 in the previous year, but the expected revenues from these treatments fell around 30% to $211B. The trend highlights how productivity is declining in the R&D labs of Big Pharma as it struggles to offset the latest patent cliffs.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs
Next headline on your portfolio: